BrightSpring Health Services Announces Onco360® Was Selected as National Pharmacy Partner for OJEMDA™
20 May 2024 - 9:30PM
BrightSpring Health Services (“BrightSpring” or “BrightSpring
Health Services”) (NASDAQ: BTSG) is proud that its company,
Onco360®, one of the nation’s largest independent oncology
pharmacies, is being selected as a pharmacy partner by Day One
Biopharmaceuticals for OJEMDA™, a cutting-edge treatment for
children diagnosed with certain central nervous system tumors.
The FDA-approved treatment is specifically used for patients six
months and older with relapsed or refractory pediatric low-grade
glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600
mutation. LGG is the most common central nervous system tumor in
children, representing 30% of pediatric brain tumors. BRAF is the
most commonly altered gene in pediatric LGG, as 75% of patients
have BRAF alterations.
“We’re proud of the work that Onco360® is doing to improve the
lives of adults and children battling cancer,” said BrightSpring’s
President and CEO, Jon Rousseau. “They are partnering at the
forefront of pharmaceutical innovation and their pharmacy
collaboration with Day One Biopharmaceuticals for OJEMDA™ is
evidence of their commitment to administering best-in-class
oncology medications. This is yet another therapeutic that will
have far-reaching health and clinical benefits for children living
with central nervous system tumors.”
“At Onco360®, we’re always looking for partnerships to advance
groundbreaking treatment options for rare cancers. We’re proud to
partner with Day One Biopharmaceuticals to become a specialty
provider for OJEMDA™,” said Benito Fernandez, Chief Commercial
Officer at Onco360®. “This innovative once-weekly, oral medication
will give children with pediatric LGG and their families hope for
remission.”
The FDA approval for OJEMDA is based on the ongoing multicenter,
open-label, single-arm FIREFLY-1 clinical trial. Eligible patients
were required to have a relapsed or refractory pediatric LGG
harboring an activating BRAF alteration based on local laboratory
testing. Continued approval for this drug will be based upon
verification and clinical benefit in the ongoing confirmatory
trials.
Onco360® operates with the mission of improving the lives
of patients battling cancer. The pharmacy has robust access to
limited distribution oncology medications and offers personalized
services such as financial assistance sourcing, expert clinical
counseling, insurance benefit verification, and digital
support.
To learn more about Onco360® and BrightSpring, please visit
https://www.brightspringhealth.com/.
About BrightSpring Health
Services BrightSpring Health Services is the parent
company of leading service lines that provide complementary and
integrated home- and community-based pharmacy and health solutions
for complex populations in need of specialized and/or chronic care.
Through the company’s service lines, including pharmacy, primary
care and home health care, and rehabilitation and behavioral
health, we provide comprehensive care and clinical solutions in all
50 states to over 400,000 customers, clients and patients
daily.
About Onco360 Oncology PharmacyOnco360 is one
of the nation’s largest independent Oncology Pharmacy and clinical
support services company. Onco360 was founded in 2003 to bring
together the stakeholders involved in the cancer treatment process
and serve the specialized needs of oncologists, patients,
hospitals, cancer centers of excellence, manufacturers, health
plans, and payers. It dispenses nationally through its network of
URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is
headquartered in Louisville, Kentucky, and is a flagship specialty
pharmacy brand of PharMerica Corporation, a leading institutional
pharmacy, specialty infusion, and hospital services company
servicing healthcare facilities in the United States. For more
information about Onco360, please visit onco360.com.
Media Contact: Leigh
WhiteLeigh.white@brightspringhealth.com 502.630.7412
BrightSpring Health Serv... (NASDAQ:BTSG)
Historical Stock Chart
From May 2024 to Jun 2024
BrightSpring Health Serv... (NASDAQ:BTSG)
Historical Stock Chart
From Jun 2023 to Jun 2024